Meeting Report

Modern Management of Classical Hodgkin Lymphoma

Presented by Amy Goodrich, CRNP, and Jose D. Sandoval-Sus, MD

Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland; and Moffitt Malignant Hematology and Cellular Therapy at Memorial Healthcare System, Tampa, Florida

Presenters’ disclosures of conflicts of interest are found at the end of this article.


J Adv Pract Oncol 2019;10(3):287–292 | https://doi.org/10.6004/jadpro.2019.10.3.16 | © 2019 Harborside™


  

ABSTRACT

Thanks to the introduction of checkpoint inhibitors, patients with classical Hodgkin lymphoma have a better chance at living longer with the disease. However, treatment-related side effects can impact quality of life in the short- and long-term. Amy Goodrich, CRNP, and Jose D. Sandoval-Sus, MD, provided strategies for preventing and mitigating these adverse events.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.